Table 7.
Multivariate analysis of factors associated with nintedanib discontinuation within 3 and 12 months
| Discontinuation within 3 months | Discontinuation within 12 months | |||
|---|---|---|---|---|
| OR (95% CI) | p-valuea | OR (95% CI) | p-valuea | |
| Age, ≥ 75 vs. < 75 years | 1.38 (1.15–1.66) | < 0.001 | 1.29 (1.10–1.52) | 0.002 |
| Sex, female vs. male | 0.72 (0.57–0.92) | 0.010 | 0.69 (0.56–0.86) | 0.001 |
| BSA, < 1.58 vs. ≥ 1.58 m2 | 1.78 (1.45–2.20) | < 0.001 | 2.01 (1.67–2.43) | < 0.001 |
| IPF severity stage, III + IV vs. I + II | 1.29 (1.06–1.57) | 0.012 | 1.32 (1.12–1.55) | < 0.001 |
| FVC % predicted, < 70 vs. ≥ 70% | 1.75 (1.44–2.12) | < 0.001 | 2.06 (1.76–2.41) | < 0.001 |
| Occurrence of ADR (diarrhoea), yes vs. no | 0.53 (0.41–0.70) | < 0.001 | 0.43 (0.36–0.50) | < 0.001 |
| Occurrence of ADR (hepatic function disorder), yes vs. no | 1.65 (1.36–2.01) | < 0.001 | 1.09 (0.92–1.29) | 0.313 |
ADR adverse drug reaction, BSA body surface area, CI confidence interval, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, OR odds ratio
aChi-squared test